NCT06374602View on ClinicalTrials.gov

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

March 25, 2026

Study Completion Date

June 25, 2026

Conditions
Anaplastic Thyroid Cancer
Interventions
DRUG

Pembrolizumab + Lenvatinib

Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody. Lenvatinib is Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).

Trial Locations (1)

190020

RECRUITING

Saint Petersburg State University Hospital, Saint Petersburg

All Listed Sponsors
lead

Saint Petersburg State University, Russia

OTHER